EGF as a biologic switch in hair growth cycle
SUMMARY
The hair growth cycle consists of three stages known as the anagen (growing), catagen (involution) and telogen (resting) phases. This cyclical growth of hair is regulated by a diversity of growth factors. Whereas normal expression of both epidermal growth factor and its receptor (EGFR) in the outer root sheath is down-regulated with the completion of follicular growth, here we show that continuous expression of epidermal growth factor in hair follicles of transgenic mice arrested follicular development at the final stage of morphogenesis. Data from immunoprecipitation and immunoblotting showed that epidermal growth factor signals through EGFR/erbB2 heterodimers in skin. Furthermore, topical application of tyrphostin AG1478 or AG825, specific inhibitors of EGFR and erbB2 respectively, completely inhibited new hair growth in wild type mice but not in transgenic mice. When the transgenic mice were crossed with waved-2 mice, which possess a lower kinase activity of EGFR, the hair phenotype was rescued in the offspring. Taken together, these data suggest that EGFR signaling is indispensable for the initiation of hair growth. On the other hand, continuous expression of epidermal growth factor prevents entry into the catagen phase. We propose that epidermal growth factor functions as a biologic switch which is turned on and off in hair follicles at the beginning and end of the anagen phase of the hair cycle, guarding the entry to and exit from the anagen phase.
INTRODUCTION
The hair follicle is a regenerating system which undergoes cycles of renewal in three phases known as anagen, catagen, and telogen. Various signaling molecules are involved in different phases of hair growth (1) . However, the mechanisms underlying the switch from phase to phase remain largely unknown. Among the many growth factors expressed in association with the development of hair follicles, epidermal growth factor (EGF 1 ) is known for its effects on skin and hair development (2) . Subcutaneous administration of EGF for 2 weeks into neonatal mice delayed the development of hair follicles and epidermis. Both the growth of hair bulbs and hair fiber production were retarded. The proliferative activity of the epidermis at birth was maintained for 8 days, resulting in a thicker epidermis compared to control mice. However, the delay in skin development was not prolonged, and the mitotic index and thickness of the epidermis declined to that of control values a few days later. By day 41, final hair length and diameter were not significantly reduced (3) . EGF also had no effect on back skin when injected into mice with ages ranging from 12-20 days (2). The authors suggested that EGF was only active in skin during the neonatal period. In contrast, EGF induces follicle regression besides inhibiting hair fiber production and stimulating mitosis of the basal epidermal cells when infused into adult sheep (4) . Subsequently, in vitro studies with isolated human hair follicles have shown that EGF stimulates DNA synthesis in the outer root sheath and hair follicle elongation but inhibits hair fiber production. DNA synthesis in the matrix cells is inhibited and they remain connected to the dermal papilla by a thin strand of epithelial cells, inducing an artificial catagen-like effect (5) . Despite all these early studies, the physiological role of EGF on hair development and the signaling pathways involved remain unclear. It has been shown that administration of anti-EGF serum can cause accelerated hair growth in new born mice (6) . This suggests that endogenous EGF acts as an inhibitory molecule during follicle morphogenesis.
There are four members of the EGF receptor family namely EGFR or erbB1, erbB2, erbB3 and erbB4. EGF, transforming growth factor (TGF) α, amphiregulin, and possibly epigen (7) bind EGFR which can subsequently form homodimers or heterodimers with any erbB receptors, whereas β-cellulin, epiregulin and heparin binding-EGF are ligands for both EGFR and erbB4 (8) . A null mutation in EGFR is lethal during embryonic development.
Only certain strains of mutant mice can survive up to three weeks after birth, with severe impairment in development of multiple organs including skin and failure of hair growth (9) (10) (11) . Hair follicles in the neonatal skin cannot develop normally even when grafted to nude mice (12) . In transgenic mice expressing a dominant negative mutant of EGFR in the epidermis and outer root sheath, the hair follicles cannot progress through follicle morphogenesis and eventually undergo necrosis (13) . A loss of function mutation in TGFα (14, 15) or a specific point mutation in EGFR (16,17) results in a less severe phenotype of curly whiskers and pronounced waviness of first hair coat. Irregularly distributed hair follicles were found in the dermis and subcutis layers. Surprisingly, triple null mice lacking EGF, amphiregulin and TGFα demonstrate the same hair and skin phenotype as the TGFα null mice (18) . This suggests that other members of the EGF family can compensate for the loss of the three EGFR ligands. Transgenic mice over-expressing the various EGFR ligands in skin are useful for addressing their specific roles.
Both amphiregulin and heparin binding-EGF are expressed in skin (19, 20) . Upon culture of keratinocytes, the expression of both molecules increases and they become the major autocrine factors for proliferation (21 
Generation of transgenic mice
The full length mouse Egf cDNA of 4.6 kb was isolated from a C57BL/6 kidney cDNA library (Life Technologies, USA) and confirmed by sequencing. EGF transgenic mice were established using the promoter from cytomegalovirus to drive full length Egf cDNA joined to an SV40 polyA. The injection fragment of 6.5 kb was released and purified using the QIAEX gel extraction kit (Qiagen, USA), then passed through a spin-X column (Costar, USA). The purified DNA fragment was introduced at 6-8ng/µl into the pronucleus of FVB/N embryos by standard microinjection procedures (26) . Transgenic mice were identified by PCR of tail DNA using primers for Egf cDNA and confirmed by Southern blotting (data not shown). The primer sequences (5' to 3') were gagaatgccgcctgcaccaacac and agggttctttggggggtttgatag, giving a PCR product of 435 bp.
Immunohistochemistry
The locations of EGF expression on dorsal skin in heterozygous animals were determined at birth ( min. The sections were washed again and incubated for 5 min with a 1 mg/ml chromogen solution (Dako). After counterstaining with haematoxylin, the sections were dehydrated and mounted with Permount. As negative controls, the primary antibody was omitted or replaced with the same concentration of rabbit IgG (Dako). To confirm signal specificity, the primary antibody was blocked with 15 µg/ml mouse EGF (Peprotec Inc., Israel) at 4 °C overnight before use.
TUNEL Assay
The procedures recommended for the Apoptosis Detection kit (Promega Ltd, WI, USA) were followed on fixed frozen skin sections.
Measurement of skin thickness
Haematoxylin and eosin (H&E) staining was performed on frozen sections (three heterozygous mice per time point, with control mice from nontransgenic littermates). Three representative sections for each sample were analyzed using a Leica DMRB microscope. The thickness of epidermal, dermal and subcutaneous layers was measured on digital images using the Stereo Investigator 4.0 software (Leica Ltd., Germany). A total of 50 data sets were EGF as a biologic switch in hair growth cycle 8 collected from the three samples at each time point. All data were reported as mean ± SD and analyzed using the two-tailed unpaired Student's t test.
Protein preparation and immunoblotting
Mice were sacrificed by cervical dislocation, and mid dorsal skin, liver and brain were immediately collected for protein preparation. Tissues were homogenized in 20 mM Hepes, pH7.4, 2 mM MgCl 2 , 100 µg/ml phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and 2 µg/ml aprotinin. The homogenized samples were centrifuged at 4 °C for 5 min and the supernatants were collected. Samples (80 µg aliquots as determined by the Coomassie Blue dye binding assay; Bio-Rad, USA) were separated on a 7.5% polyacrylamide gel and transferred to a Hybond-ECL membrane (Amersham Pharmacia Biotech, NJ, USA). For immunoblotting, the procedures in the chemiluminescent detection system (ECL Detection System; Amersham Pharmacia Biotech) were followed. The primary antibodies and working concentrations were: rabbit anti-mouse EGF (Upstate, 2 µg/ml ); mouse anti-human EGFR (Transduction lab, UK, 1µg/ml); rabbit anti-mouse erbB2 (Santa Cruz, CA, USA, 0.2 µg/ml); rabbit anti-mouse erbB3 (Santa Cruz, 0.2 µg/ml); mouse anti-phosphotyrosine PY20
(Transduction lab, 1 µg/ml). The secondary antibodies and working dilutions were: goat antimouse IgG (Transduction lab, 1:5000); goat anti-rabbit IgG (Amersham, Pharmacia Biotech, 1:4000).
Immunoprecipitation
Specific antibody (1µg) was added to 500 µg of crude protein samples and the mixture was made up to a final volume of 0.5 ml with IP buffer [1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 10 mM Tris (pH 7.4), 1 mM EDTA, 1 mM EGTA (pH 8.0), 1 mM Na 3 VO 4 , 100 µg/ml phenylmethylsulfonyl fluoride, and 2 µg/ml aprotinin]. Samples were incubated at 4°C for 2 hours with gentle rocking. Protein A or G /agarose (40 µl) was then added and incubation was continued for 2 hours. The samples were centrifuged for 1 min at 4 °C and the supernatants discarded. The agarose beads were washed with 1 ml IP buffer at 4°C for 5 min. The samples were spun down and the washing procedures repeated 3 more times. Finally, 40 µl of sample buffer with 5% β-mercaptoethanol were added to the agarose beads and the samples used for immunoblotting.
Topical application of the erbB1 inhibitor AG1478 and erbB2 inhibitor AG825
Heterozygous transgenic mice (Day 23, n=4) and nontransgenic littermates (n=4)
were each divided into two groups of treatment and control animals. Tyrphostin AG1478
(10µg, Sigma, CA, USA) or Tyrphostin AG825 (60µg, Sigma) was dissolved in 1 ml DMSO and then mixed with 2 g of a neutral aqueous cream base (Orjon, Australia). An area starting midway along the back of the mice was shaved one day before application of the inhibitor or cream base. AG1478 or AG825 cream was applied topically every day for 15 consecutive days. In the case of the controls, only the cream base was administered. Each treatment was repeated on three litters (n=8). For large litters of more than 8 mice, 10µg AG1478 together with 60µg AG825 were added to 1ml DMSO, mixed with 2g cream and applied to the rest of the litter.
RESULTS

Characterization of EGF transgenic mice
While seven transgenic lines were generated with the CMV-Egf construct, only one line, designated 62.7, manifested phenotypic changes and the heterozygous animals were used for detailed analysis here. Line 62.7 exhibited thin hair, curly vibrissae and stunted growth (Fig 1a, b) . Homozygous bred transgenic mice showed an even more severe phenotype and appeared to be nearly nude. When bred into different genetic backgrounds, including C57BL/6, ICR, F1 hybrid of C57BL/6 and FVB, transgenic progeny showed similar hair phenotype as the FVB founder (not shown). From immunohistochemistry, EGF was expressed in the sebaceous glands, outer root sheath of hair follicles, stratum granulosum and basal keratinocytes of the epidermis during follicular morphogenesis in wild type mice (Fig 1c,d) . The EGF expression in hair follicles was switched off once they had entered the telogen phase (Fig 1e) . In contrast, transgenic mice demonstrated constitutive expression of EGF in the hair follicles (Fig 1f, g, h ) which appeared to remain in stage 7 to 8 of follicular morphogenesis according to published guidelines by Paus (28) . Results from RT-PCR and immunoblotting confirmed that EGF was strongly expressed in the skin of 62.7 mice with accumulation of the EGF precursor, which was in contrast to age-matched wild type mice ( Fig.1 i) . EGF protein could also be detected in the liver and brain of transgenic animals and this subtle phenotype is still under investigation. Only increased levels of EGF mRNA, but not of protein, were detected in other transgenic lines which correlated with the absence of abnormalities in the skin or other organs at the morphological or histological level.
Association of EGF expression with structural changes in the skin and hair cycling
From H&E stained sections (Fig 2) , wild type mice and transgenic mice had the same skin histology at birth (Day 1, Fig 2a, b) . However, at Day 4, retardation of hair follicle and skin development was observed in the transgenic mice (Fig 2c, d) . Although more than 90% of hair follicles had grown into the subcutis layer (stage 7 and 8), an increase in hair follicle size and total skin thickness was obvious in the wild type mice only. Furthermore, transgenic skin samples showed a thicker epidermis when compared to wild type animals at Day 4.
There was an increase in the number of cell layers at the basal layer as well as the stratum corneum, which suggested epidermal hyperproliferation and a delay in epidermal differentiation (Fig 2c, d insets) . The hair follicles in wild type animals were in the dermis layer as the hair cycle proceeded to the catagen/telogen phase at Day 21 (Fig 2e, f and no hair follicles of catagen or telogen phase were observed at any of these time points.
Furthermore, no apoptotic cells were detected in either the lower bulb or the root sheath of transgenic follicles by TUNEL staining at any of the time points studied (not shown). This has been used to distinguish the late anagen follicles from those in early catagen (1) . At Day 50, some telogen follicles could be occasionally found in certain transgenic animals. Skin thickness was measured using computer assisted morphometric software (Fig 3a) . In general, total skin thickness in transgenic samples was less than in controls from newborn to around Day 14 after birth (p<0.05). However, as total skin thickness decreased in wild type mice when progressing through the hair cycle, transgenic skin became thicker than that of controls (p<0.05). The reduced skin thickness in transgenic mice in the first 14 days was mainly contributed by the subcutis (Fig 3d) (p<0.05) . In contrast, the increase in thickness observed after Day 21 involved the epidermis, the dermis and the subcutis layers (Fig 3b-d) .
Furthermore, the hair shaft diameter of hair plugged from back skin was only half that of controls, although the percentage of various types of hair did not change (not shown).
EGFR signaling in hair development as revealed by immunoblotting
Next, we investigated the pathway of EGF signaling in wild type and transgenic skin.
EGFR was readily detected in crude skin lysates of both transgenic and wild type mice at Day 7 and Day 14 (Fig 4a) . The receptors were strongly phosphorylated during this period which suggested that there was activation of downstream pathways for hair growth. However at After relating the expression of various erbB receptors to follicle morphogenesis and the hair cycle, we attempted to identify the dimerization partner(s) of erbB1 by immunoprecipitation using antibodies specific for either erbB2 or erbB3 (Fig 4b) . For Day 14 samples, both erbB2 and erbB3 immunoprecipitates were phosphorylated at a comparable level in both transgenic and wild type skin samples. EGFR could be detected in both immunoprecipitates, implying EGFR/erbB2 and EGFR/erbB3 heterodimer formation in Day 14 skin samples. In contrast, for Day 35 skin, erbB2 activation was detected in transgenic but not in wild type mice and EGFR could be detected in erbB2 immunoprecipitates. Neither erbB3 activation nor EGFR/erbB3 heterodimerization was detected in transgenic or wild type samples at Day 35. Since erbB2 has no known ligand and requires a dimerization partner for phosphorylation, we conclude that erbB2 activation persisted in the transgenic skin through heterodimerization with EGFR.
Topical application of erbB blockers
Our data suggested that EGF signaling through EGFR/erbB2 and EGFR/erbB3 may be important in follicle growth and perhaps during the anagen phase of the hair cycle. We tested this hypothesis in vivo using control and transgenic mice. Either tyrphostin AG1478 or AG825, selective inhibitors of EGFR and erbB2 tyrosine kinase activity respectively, was administered to the skin of adult mice. An area on the dorsal side was shaved one day before the first inhibitor application (Fig 5a,b) . Shaving could induce anagen (31) and allow easy assessment of hair growth. After 15 consecutive days of treatment, wild type mice treated with vehicle only had a new layer of hair (Fig 5e) whereas in wild type mice treated with either inhibitor, new hair growth was completely inhibited (Fig 5c) . Skin histology after treatment showed that hair follicles were in the anagen phase of the hair cycle (not shown).
In contrast, tyrphostin treated transgenic mice showed continuous hair growth (Fig 5d) , although less dense hair was observed compared to the vehicle-treated transgenic mice (Fig   5f) . Similar results were obtained when both inhibitors were applied simultaneously and there was a more obvious reduction in hair density. Furthermore, new hair growth in the transgenic mice treated with both inhibitors was two days slower than that of transgenic mcie treated with a single inhibitor. Within the vehicle treated group, new hair growth in wild type mice was slower than in transgenic mice by two days. These data suggest that EGFR/erbB2 signaling is indispensable for hair growth.
Rescue by breeding with waved-2 mice
To further demonstrate that thin fur in line 62.7 was due to EGF overexpression and upregulated EGFR signaling, transgenic mice were mated with waved-2 mice. Homozygous waved-2 mutant mice (Egfr wa-2/wa-2 , Fig 6a) were bred with homozygous 62.7 transgenic mice (CMV-Egf/CMV-Egf). All offspring were therefore double heterozygous for both genes (Egfr wa-2/+ , CMV-Egf/+). They all showed normal hair growth throughout the body (Fig 6b) .
Overexpression of EGF in double heterozygous mice was confirmed by immunoblotting. As expected, the level of EGF precursor detected in the skin of such mice was similar to that of heterozygous 62.7 mice (not shown). When heterozygous waved-2 mice were bred with homozygous 62.7 transgenic mice, 17 out of 37 of the offspring had thin fur, indicating that the genetic rescue was due to the waved-2 mutation instead of other differences in the genetic background.
Histological sections taken from the back skin showed that the hair follicles of double heterozygous mice were very similar to that of wild type mice at Day 7 (Fig 6c,e) . More importantly, at Day 21 the hair follicles in the double heterozygous mice were in the dermis layer and the subcutis layer had reduced in thickness, in contrast to that of 62.7 transgenic mice (Fig 6f-h ). This indicated that hair follicles in the double heterozygous mice had already entered the telogen phase.
DISCUSSION
Based on the earlier studies of EGF in relation to skin and hair development and given that the EGFR family and ligands play a pivotal role in skin development, we have investigated the role of EGF and its signaling mechanism with the aid of a transgenic mouse line constitutively expressing EGF in skin and hair follicles. To our surprise we have found that constitutive expression of EGF inhibits entry into the catagen phase. Furthermore, EGFR/erbB2 signaling appears to be indispensable for hair growth.
In mice, follicular morphogenesis began at day 14.5 of embryonic development and lasted until around 3 weeks after birth (32) . The present study showed that even when EGF was overexpressed, the skin histology was normal at birth. By Day 4, there was an increase in epidermal thickness but a decrease in both overall skin thickness and hair follicle diameter, consistent with earlier studies which involved the injection of EGF into newborn animals and
showed an inhibitory role of EGF in skin development (2, 3) . It has also been shown that whereas EGFR is expressed continuously in the epidermis, expression in the hair follicles started a few days after birth. This correlates with the onset of disorganized hair follicle phenotype in loss-of function mouse mutants of EGFR generated by homologous recombination or expression of a dominant negative EGFR transgene (12, 13) . Some hair follicles even penetrate the underlying muscle layer a few days later (13) . These data underscore the importance of EGFR signaling in controlling hair follicle orientation and elongation. The novel finding here is that continuous expression of EGF leads to arrest of the hair follicles at stage 8 of follicular morphogenesis. This conclusion appears to be in contrast to previous reports of catagen-promoting activity in sheep (4, 21) but this effect may be an artifact due to the high doses of EGF used. At lower doses of EGF, there was a reduction in follicle bulb size and a reduction in wool fiber diameter, similar to that observed in our transgenic mice. At higher doses, EGF induces wool follicle regression (4). This is likely to be due to the excessive inhibition of EGF in bulb cell division which may subsequently lead to the observed increase in apoptosis (33) . Also, in cultured human hair follicles, the stimulation of hair follicle elongation and outer root sheath proliferation by EGF but inhibition on the proliferation of matrix cells could lead to an artificial catagen. The matrix cells remained connected to the dermal papilla by a thin strand of epithelial cells (5) and this epithelial strand is also seen in follicles at certain stages of catagen (29) . In summary, all reports point to a stimulatory effect of EGF on the proliferation of basal keratinocytes and outer root sheath cells but inhibition on proliferation of bulb cells.
Is EGF the physiologic ligand in controlling hair cycling? Various transgenic mouse lines have been produced to address the specific roles of EGF family ligands in skin development with the aid of the promoter from keratin 14 to drive transgene expression in the basal epidermis and outer root sheath. Amphiregulin, heparin binding-EGF and TGFα produce different effects when over-expressed in skin (see Introduction). Arrest in hair cycle progression has not been reported in these mice. Furthermore, our EGF transgenic mice were not prone to develop papillomas after skin lesions or during aging as reported for TGFα mice (data not shown). From our immunoblot data it appears that EGF is likely to act through EGFR/erbB2 dimerization. Furthermore, switching EGF off is associated with progression of follicle morphogenesis to the catagen phase.
The present data using tyrphostins on mice at day 23 point to the indispensable role of EGFR/erbB2 signaling in the initiation of hair growth in the hair cycle. In wild type mice treated with the specific EGFR inhibitor, no new hair growth was seen. The same result was obtained using the specific inhibitor for erbB2, indicating that EGFR/EGFR signaling is inadequate for hair growth. Since erbB2 does not have its own ligand but signals through heterodimerization (8), our results indicate that EGFR/erbB2 signaling is involved. In contrast, tyrphostin treated transgenic mice continued to generate new hair, but at a lower density. It is possible that with continuous overexpression of EGF in the transgenic mice, the inhibition of EGF signaling with either tyrphostin is incomplete. Furthermore, in vehicle treated mice, the transgenic mice were found to exhibit new hair growth much sooner than the wild type mice suggesting that EGF is important for the initiation of hair growth. It is interesting to note that in TGFα null mutant mice, hair regrowth after plucking is faster than that in wildtype mice (15). One intriguing possibility is that EGF is more important than other EGFR ligands in stimulating hair regrowth, and that TGFα competes with EGF for available EGFR. One of the important downstream signaling molecules may be Stat3. Although hair follicles in Stat3-disrupted mice can progress through follicle morphogenesis to telogen, they cannot progress to anagen. Importantly, keratinocytes isolated from these mice lack the normal response of migration to EGF (34) . These data clearly indicate that the molecular control of hair growth during morphogenesis, although often referred as the 'first anagen', is different from anagen in subsequent hair cycles. We believe that EGF expression in the outer root sheath of hair follicles is important for downward growth of the hair follicle. EGF expression needs to be turned off before progression of the hair follicles to telogen. In subsequent hair cycles, EGF is again important for downward growth of the hair follicles and production of the hair shaft. Although it remains to be determined whether continuous EGF can lead to anagen arrest in the hair cycle, we would like to propose that EGF acts as a biologic switch guarding entry to and exit from the anagen phase of the hair cycle, as depicted in Fig. 7 . The expression patterns of both EGF and its receptor are consistent with such a role. EGF, together with various other signaling molecules, forms a complex network for the precise control of the hair cycle. For example, fibroblast growth factor 5 is required for the transition to catagen. When the gene is mutated in mice, hair follicles fail to progress to the catagen phase and this gives rise to an abnormal long hair phenotype (35) .
The findings of this study may be relevant to new therapeutic approaches for the treatment of abnormally thin hair caused by abnormal EGFR signaling. On the other hand, prevention of unwanted hair growth can be achieved by topical application of EGFR/erbB2
inhibitors. For example, such a strategy may be of benefit in the treatment of women suffering from hirsutism or for cosmetic purposes. 
